Pseudomembranous colitis: pathogenesis and therapy.
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001285:Atropine / Q000627:therapeutic use; D001414:Bacitracin / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000032:analysis*; D002792:Cholestyramine Resin / Q000627:therapeutic use; D003013:Clostridium / Q000302:isolation & purification; D003015:Clostridium Infections / Q000175:diagnosis*; D003084:Colestipol / Q000627:therapeutic use; D004157:Diphenoxylate / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000209:etiology*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology; D008795:Metronidazole / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005765:Gastrointestinal Agents; D002792:Cholestyramine Resin; D001414:Bacitracin; D008795:Metronidazole; C002534:atropine sulfate-diphenoxylate hydrochloride drug combination; D014640:Vancomycin; D004157:Diphenoxylate; D001285:Atropine; D001905:Botulinum Toxins; D003084:Colestipol